ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "T Cell"

  • Abstract Number: 1804 • ACR Convergence 2024

    Investigating Adaptive Immune Receptor Repertoires by Deep Immune Cell Phenotyping in Preclinical Autoimmunity Development

    Aleksandra Bylinska1, Miles Smith1, Rufei Lu1, Benjamin Jones2, Carla Guthridge1, Matthew Caleb Marlin1, Christian Wright3, Susan Macwana3, Wade DeJager3, Marci Beel3, Christopher Lessard1, Cristina Arriens1, Joan Merrill4, Judith James1 and Joel Guthridge1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Oklahoma State University, Oklahoma City, OK, 3Oklahoma Medical Research Foundation, Oklahoma City, 4Oklahoma Medical Research Foundation, Oklahoma City 73104, OK

    Background/Purpose: A loss of systemic self-tolerance to anti-nuclear autoantibodies (ANAs) is one of the main hallmarks of SLE. However, most healthy females with ANAs will…
  • Abstract Number: 1854 • ACR Convergence 2024

    TCR-Nck Modulators: Pioneering Oral Modulation of T Cell Receptor Activation Holding the Promise of Treating Autoimmune Diseases

    Christopher VanDeusen1, Shannon Dwyer2, Aldo Borroto3, Andres Gagete1, D Scott Batty Jr1 and Balbino Alarcon3, 1Artax Biopharma, Inc, Cambridge, MA, 2Artax Biopharma, Inc., Cambridge, 3Centro de Biología Molecular Severo Ochoa, Madrid, Spain

    Background/Purpose: Loss of T-cell tolerance to self-antigens underlies the development of all autoimmune diseases, and despite progress, there remains a significant unmet need for patients.…
  • Abstract Number: 2256 • ACR Convergence 2024

    Depletion of Citrullinated Vimentin-reactive Follicular Helper T Cells with Treatment-induced Remission of Recent-onset Rheumatoid Arthritis When Compared to Non-remission at 6 Months

    Jia Yi Hee1, Hendrik Nel2, Yann Abraham3, Katrina Chakradeo4, Michelle Roch4, Tom Lynch5, Lyn March5, Mihir Wechalekar6, Helen Keen7 and Ranjeny Thomas8, 1The University of Queensland, Woolloongabba, Queensland, Australia, 2Frazer Institute, The University of Queensland, Translational Research Institute, Brisbane, Australia, 3Janssen Research and Development, Beerse, Belgium, 4The University of Queensland, Brisbane, Australia, 5The University of Sydney, Sydney, New South Wales, Australia, 6Flinders Medical Centre, Adelaide, Australia, 7Fiona Stanley Hospital, Murdoch, Western Australia, Australia, 8University of Queensland, Brisbane, Australia

    Background/Purpose: More than 50% of people with new-onset RA may achieve remission within the first year on conventional synthetic (cs)-DMARDs. Sustained remission confers better long-term…
  • Abstract Number: 0016 • ACR Convergence 2024

    Establishment of a Human 3D In-Vitro Lymphoid Model to Evaluate Germinal Center Biology

    Lichchavi Rajasinghe1, Govinda Rocky Thomas,2, Jee Ho Lee1, Gary Sims1 and Tatiana Ort1, 1Immunology Biosciences, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, 2AstraZeneca Pharmaceuticals, Gaithersburg, MD

    Background/Purpose: Germinal centers (GC) are specialized lymphoid structures found within the B cell follicles of secondary lymphoid tissue formed following infection or immunization. They are…
  • Abstract Number: 0811 • ACR Convergence 2024

    High-Throughput Proteomic Profiling of Longitudinal Serum Samples to Predict Treatment Response in Lupus Nephritis

    Benjamin Jones1, Rufei Lu2, Andrea Fava3, Peter Izmirly4, Jennifer Anolik5, Chaim Putterman6, David Wofsy7, Matthias Kretzler8, Celine Berthier9, E. Steven Woodle10, Michael Weisman11, Mariko Ishimori12, The Accelerating medicines Partnership: RA/SLE Network13, Betty Diamond14, Jill Buyon15, Michelle Petri16, Judith James13 and Joel Guthridge13, 1Oklahoma State University, Oklahoma City, OK, 2University of California San Francisco, San Bruno, CA, 3Johns Hopkins University, Baltimore, MD, 4New York University Grossman School of Medicine, New York, NY, 5University of Rochester Medical Center, Rochester, NY, 6Albert Einstein College of Medicine, Safed, Israel, 7University of California San Francisco, SF, CA, 8University of Michigan, Ann Arbor, MI, USA, Ann Arbor, MI, 9University of Michigan, Ann Arbor, MI, 10University of Cincinnati College of Medicine, Cincinnati, OH, USA, Cinncinnati, OH, 11Stanford University, Los Angeles, CA, 12Cedars-Sinai Health System, Los Angeles, CA, 13Oklahoma Medical Research Foundation, Oklahoma City, OK, 14The Feinstein Institutes for Medical Research, Manhasset, NY, 15NYU Grossman School of Medicine, New York, NY, 16Johns Hopkins University School of Medicine, Timonium, MD

    Background/Purpose: Lupus nephritis (LN) can lead to severe morbidity and early mortality in SLE patients. While therapeutic options for LN have improved, they are not…
  • Abstract Number: 1490 • ACR Convergence 2024

    Multi-centered Clinical Validation of T Cell-bound C4d (TC4d) and T Cell Autoantibodies (TIgG and TIgM): Sensitive and Specific Biomarkers of SLE with Enhanced Accuracy Compared to Conventional SLE Tests

    Vasileios Kyttaris1, Andrew Concoff2, Touba Warsi3, Sepehr Taghavi3, Sudha Kumar3, Stanley Park3, Abigail Patalinghug3, Christine Schleif3, Brittany Partain4, Joseph Ahearn5, Nicole Wilson6, Chau-Ching Liu6, Susan Manzi6 and Tyler O'Malley7, 1BIDMC, Boston, MA, 2Exagen, Inc., Los Angeles, CA, 3Exagen, Carlsbad, CA, 4Exagen, Boston, MA, 5Allegheny Health Network, Wexford, PA, 6Allegheny Health Network, Pittsburgh, PA, 7Exagen, Vista, CA

    Background/Purpose: Conventional SLE diagnostic markers lack sensitivity and are biased towards severe disease, resulting in a subset of clinically ambiguous ANA-positive but specific autoantibody-negative patients.…
  • Abstract Number: 1836 • ACR Convergence 2024

    Transcriptional Changes in the Formation of Tissue Resident Memory T Cells in the Joint

    Yang Yang1, Yusuke Miyashita1, Vitor Aguiar1, Maria Gutierrez-Arcelus1, Kellen Winden2, Peter Nigrovic3 and Margaret Chang1, 1Boston Children's Hospital, Boston, MA, 2Boston Children's Hospital, Boston, MA, 3Boston Children's Hospital, Brookline, MA

    Background/Purpose: Rheumatoid arthritis is a chronic autoimmune disease characterized by joint-specific memory, the phenomenon in which arthritis repeatedly flares in the same joints. We previously…
  • Abstract Number: 1855 • ACR Convergence 2024

    ­Identification of Autoreactive Cytotoxic T Cells in ANCA-Associated Vasculitis

    Laura van Dam1, Shady Younis2, Jae-Seung Moon3, Mengrui Zhang4, Shima Parfasar4, Audra Horomanski3, orr Sharpe3, Jolijn van Leeuwen5, Tobias Lanz4, Cees van Kooten6, Onno Teng7 and William Robinson8, 1Stanford, Palo Alto, CA, 2Stanford University, Stanford, CA, 3Department of Immunology and Rheumatology, Stanford University, Stanford, CA, 4Department of Immunology and Rheumatology, Stanford University, Stanford, 5Department of Nephrology, Leiden University Medical Center, Leiden, Netherlands, 6Department of Nephrology, Leiden University Medical Center, Leiden, 7Leiden University Medical Center, Leiderdorp, Netherlands, 8Division of Immunology and Rheumatology, Stanford University, and VA Palo Alto Health Care System, Stanford, CA

    Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a rare and severe autoimmune disease, characterized by a pauci-immune necrotizing vasculitis leading to inflammation and damage…
  • Abstract Number: 2290 • ACR Convergence 2024

    Umbilical Cord-derived Mesenchymal Stem Cells Suppress Sjogren’s Syndrome Pathology

    Yukitomo Hagiwara1, Goh Murayama2, Taiga Kuga2, Yujin Nishioka2, Takumi Saito2, Yu Yamaji2, Tomoko Miyashita2, Makio Kusaoi3, Ken Yamaji2 and Naoto Tamura2, 1Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan, 2Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, 3Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Bunkyo, Tokyo, Japan

    Background/Purpose: Primary Sjögren's syndrome (pSS) is characterized by lymphocytic infiltration of the salivary and lacrimal glands, leading to functional loss and gradually causing dry mouth…
  • Abstract Number: 0038 • ACR Convergence 2024

    The Role of Dual Specificity Phosphatase 22 (DUSP22) in Rheumatoid Arthritis: Mechanism and Genetic Investigations

    Wei-Ting Hung1, Yi-Ming Chen2, Wen-Nan Huang3, Tsai-Hung Yen4, Tse-Hua Tan5 and Huai-Chia Chuang6, 1Taichung Veteran General Hospital, Taichung City, Taiwan (Republic of China), 2Taichung Veterans General Hospital, Taiwan, Taichung, Taiwan (Republic of China), 3Taichung Veterans General Hospital, Taichung, Taiwan, Taichung, Taiwan (Republic of China), 4Taichung Veterans General Hospital, Xitun District, Taichung City, Taiwan (Republic of China), 5National Health Research Institutes, Mao-Li, Taiwan (Republic of China), 6National Health Research Institutes, Zhunan, Taiwan (Republic of China)

    Background/Purpose: Rheumatoid arthritis (RA) is a debilitating autoimmune disorder characterized by chronic inflammation and joint damage. This study investigates the role of Dual Specificity Phosphatase…
  • Abstract Number: 0869 • ACR Convergence 2024

    Deciphering Pathogenic Phenotypes by Multi-modal Deep Single-cell Blood Immunophenotyping in Individuals At-risk for Rheumatoid Arthritis

    Jun Inamo1, Joshua Keegan2, Alec Griffith2, Tusharkanti Ghosh1, Alice Horisberger2, Kaitlyn Howard2, John Pulford2, Ekaterina Murzin2, Brandon Hancock2, Thomas Eisenhaure3, Salina Dominguez4, Miranda Gurra5, Siddarth Gurajala3, Anna Helena Jonsson1, Jennifer Seifert6, Marie Feser7, Jill Norris8, Ye Cao2, William Apruzzese9, S. Louis Bridges10, Vivian Bykerk11, Susan Goodman12, Laura Donlin11, Gary S. Firestein13, Joan Bathon14, Laura B. Hughes15, Darren Tabechian16, Andrew Filer17, Costantino Pitzalis18, Jennifer Anolik19, Larry Moreland20, Nir Hacohen21, Joel Guthridge22, Judith James22, Carla Cuda5, Harris Perlman5, Michael B. Brenner2, Soumya Raychaudhuri23, Jeffrey Sparks24, Michael Holers7, Kevin Deane25, James A. Lederer26, Deepak Rao26 and Fan Zhang27, and the Accelerating Medicines Partnership RA/SLE Network, 1University of Colorado School of Medicine, Aurora, CO, 2Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 3Broad Institute of MIT and Harvard, Cambridge, 4Northwestern University, Chicago, 5Northwestern University, Chicago, IL, 6University of Colorado and Oklahoma Medical Research Foundation, Aurora, CO, 7Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, 8Colorado School of Public Health, Denver, CO, 9Accelerating Medicines Partnership® Program: Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP® RA/SLE) Network, Boston, MA, 10Division of Rheumatology, Weill Cornell Medical College, New York, NY, 11Hospital For Special Surgery, New York, NY, 12Hospital for Special Surgery, New York 10025, NY, 13University of California, San Diego, La Jolla, 14Columbia University, New York, NY, 15University of Alabama at Birmingham Medicine, Birmingham, AL, 16University of Rochester Medical Center, Rochester, 17Rheumatology Research Group, Institute for Inflammation and Ageing, NIHR Birmingham Biomedical Research Center and Clinical Research Facility, University of Birmingham, Birmingham, United Kingdom, 18QMUL, Bromley Kent, United Kingdom, 19University of Rochester Medical Center, Rochester, NY, 20University of Colorado, Denver, CO, 21Broad Institute of MIT and Harvard, Boston, MA, 22Oklahoma Medical Research Foundation, Oklahoma City, OK, 23Brigham and Women's Hospital, Boston, MA, 24Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA, 25University of Colorado Denver Anschutz Medical Campus, Aurora, CO, 26Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 27University of Colorado, Aurora, CO

    Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease with currently no effective prevention strategies. Single-cell technologies have been recently used to investigate established RA…
  • Abstract Number: 1657 • ACR Convergence 2024

    Immunological Profiling of Pain in Knee Osteoarthritis: Treg Cells as Potential New Key Players in Symptomatic Knee Osteoarthritis

    Marie Binvignat1, Maria Marco-Salvador1, Johanna Dubois1, Paul Stys1, Alice Courties2, Fabien Pitoiset1, Alexandra Roux3, Michele Barbier4, Roberta Lorenzon2, Signe Hassler3, Claire Ribet1, helene Vantomme1, Leslie Adda1, Vanessa Mhanna1, Nicolas Coatnoan2, Gwladys Fourcade1, Vimala Didelot1, PIerre Barennes1, Lise Minssen2, Caroline Aheng1, Sanchita Bhattacharya5, Yannick Marie6, Atul J. butte5, Adrien Six1, Nicolas Tchitcheck1, Michelle Rosenzwajg1, Francis Berenbaum1, David Klatzmann1, Encarnita Mariotti-Ferrandiz1 and Jérémie Sellam7, 1Sorbonne University, Paris, France, 2AP-HP, Paris, France, 3Sorbonne University, Paris, 4AP-HP, Paris, 5UCSF, San Francisco, 6ICM, Paris, France, 7Saint-Antoine Hospital - AP-HP, Paris, Ile-de-France, France

    Background/Purpose: Pain is the main osteoarthritis (OA) symptom and remains poorly understood. While significant attention has been given to the potential role of innate immunity,…
  • Abstract Number: 1837 • ACR Convergence 2024

    Baseline Multiome Sequencing of CD45RO+CD45RA-CD4+ T Cell Reveals Distinct Immune Profiles Associated with Subsequent Response to Secukinumab Treatment

    Addison Pacheco1, Zoya Qaiyum2, Fataneh Tavasolian3, Melissa Lim4, Michael Tang1 and Robert Inman1, 1University Health Network, Toronto, ON, Canada, 2Krembil Research Institute, Toronto, ON, Canada, 3Krembil Research Institute - the University Health Network, Toronto, ON, Canada, 4University of Toronto, Toronto, ON, Canada

    Background/Purpose: Our study aims to discriminate immune profiles between secukinumab responders (SEC-R) and nonresponders (SEC-NR) in axial spondyloarthritis (axSpA) patients before biologic treatment.Methods: CD45RO+CD45RA-CD4+ T…
  • Abstract Number: 1856 • ACR Convergence 2024

    Distinct Proliferative and Special Properties of Peripheral Helper T Cells in RA Synovium

    Yuki Masuo1, Akinori Murakami1, Rinko Akamine1, Osamu Iri1, Koichi Murata1, Kohei Nishitani1, Hiromu Ito1, Takayuki Fujii1, Ryu Watanabe2, Takeshi Iwasaki1, Shinichiro Nakamura1, Shinichi Kuriyama1, Yugo Morita1, Yasuhiro Murakawa1, Chikashi Terao3, Yukinori Okada4, Motomu Hashimoto2, Shuichi Matsuda5, Hideki Ueno1 and Hiroyuki Yoshitomi1, 1Kyoto University, Kyoto, Japan, 2Osaka Metropolitan University, Osaka, Japan, 3RIKEN, Tokyo, Japan, 4The University of Tokyo / Osaka University / RIKEN, Tokyo, Japan, 5Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine, Kyoto, Kyoto, Japan

    Background/Purpose: Tertiary lymphoid structures (TLSs) are organized aggregates of immune cells that are frequently observed in the target tissues of chronic diseases. In patients with…
  • Abstract Number: 2300 • ACR Convergence 2024

    Activation of Tissue-Resident T Cells in Sjögren’s Disease with Human Salivary Organoids

    Brandon Law1, Rahmatullah Rahmati2 and Andrew Luster3, 1Massachusetts General Hospital, Boston, MA, 2Massachusetts Eye & Ear, Boston, MA, 3Massachusetts General Hospital, Charlestown, MA

    Background/Purpose: Sjögren's disease (SjD) is a chronic autoimmune disease characterized by lymphocytic infiltration of exocrine glands, particularly the salivary glands. These focal lymphocytic infiltrates are…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 21
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology